This is a routine clinical-data press release with no near-term revenue catalyst. Monitor for any subsequent FDA submissions or commercial partnership announcements tied to the Avli + Renuvion combination, but no trading action is warranted on this filing alone.
Price Chart
Executive Summary
Apyx Medical announced the publication of a small (22-patient) investigator-initiated study in Aesthetic Surgery Journal Open Forum showing that combining Avli subcision with Renuvion helium plasma radiofrequency improved cellulite and skin laxity at 180 days. Up to 81.8% of patients showed visible improvement, with histological evidence of increased collagen and elastin in a subset. This is a routine clinical-data press release with no financial figures, no regulatory submission, and no revenue impact — a modest marketing milestone for the Renuvion platform.
Key Facts
- 22-patient prospective investigator-initiated study published in Aesthetic Surgery Journal Open Forum
- Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment
- Combination approach: Avli (Tiger Aesthetics Medical) for subcision + Renuvion for helium plasma radiofrequency
- Histological analysis in a subset showed increased collagen and elastin with improved dermal architecture
- No financial data, no regulatory filing, no revenue or earnings guidance provided in the filing
Financial Impact
No financial figures disclosed; immaterial clinical-data publication
Risk Factors
- Small sample size (n=22) limits statistical significance and generalizability
- Investigator-initiated study — not a company-sponsored pivotal trial
- No FDA submission or clearance path disclosed for the combination approach
- No revenue or adoption metrics provided to quantify commercial impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018098 |
| Exhibit: ex_966637.htm | 0001437749-26-018098 |
| Document: 0001437749-26-018098-index-headers.html | 0001437749-26-018098 |
| Document: 0001437749-26-018098-index.html | 0001437749-26-018098 |
| Document: 0001437749-26-018098.txt | 0001437749-26-018098 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.41 | awaiting T+20 | — | $2.50 (+3.73%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.50 (−27.75%) |
May 21, 2026 22w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.50 (−39.47%) |
May 21, 2026 22w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.50 (−41.18%) |
May 14, 2026 23w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.50 (−42.66%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.50 (−36.22%) |
Apr 23, 2026 26w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.50 (−34.21%) |
Mar 10, 2026 33w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.50 (−27.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers